welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Guides & Guidelines
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
source: National Institute for Health and Care Excellence
year: 2016
summary/abstract:This guidance is not intended to affect the position of patients whose treatment with ataluren was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
read morerareRelated
-
Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular DystrophyObjective: Provide an overview of atalu...
-
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...
-
Study of Ataluren in >=2 to <5 Year-Old Male Participants With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
-
Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystroph...Objective: Examine the safety/tolerabil...
-
Ataluren treatment of patients with nonsense mutation dystrophinopathyIntroduction: Dystrophinopathy is a ra...
-
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dy...Duchenne/Becker muscular dystrophy (DMD/...
-
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
